MedCity News June 13, 2024
Despite misconceptions about its use, artificial intelligence (AI), through modalities such as machine learning models, is poised to enable companies to expedite the drug design process.
Drug design and development is expensive, often insufficient, and laced with the tendency for failure. Traditionally, it’s a hit-and-miss process that can stretch over a decade and consume around $2.3 billion — figures that have only climbed higher recently; with a 15% increase in costs among top global biopharmaceutical firms last year alone. However, despite misconceptions about its use, artificial intelligence (AI), through modalities such as machine learning models, is poised to enable companies to expedite the drug design process.
Designing future therapies with future technologies
The chemical universe spans over 1060...
Today's Sponsors
Today's Sponsor